Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center

The following new grants were awarded to JCCC members in May 2011:

.Principal Investigator: Judith Gasson

Sponsor Name: Susan G. Komen Breast Cancer Foundation

Award Title: "Caring Through Access and Education"

Principal Investigator: Richard A. Gatti

Sponsor Name: Cal Institute for Regenerative Medicine (CIRM)

Award Title: "Use of HIPSCS to Develop Lead Compounds for the Treatment of Genetic Diseases"

Principal Investigator: Lauren C. Pinter-Brown

Sponsor Name: Pfizer Inc. (including Warner-Lamber and Parke-Davis)

Award Title: "An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin Administered In Combination with Rituximab Compared to Defined Investigator'S Choice therapy in Subjects with Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who Are Not Candidates for Intensive High-Dose Chemotherapy"

Principal Investigator: Gary J. Schiller

Sponsor Name: Celgene Corporation

Award Title: "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell Transfusion Dependence"

Principal Investigator: David Wong 

Sponsor Name: International Association of Dental Researchers (IADR)

Award Title: "SCPSS: Enabling Technologies for Salivary Biomarkers for Clinical Research"

Principal Investigator: Kenneth Bradley

Sponsor Name: Melanoma Research Alliance

Award Title: "Repurposing Anthrax Toxin for Imaging and Treatment of Melanoma"

Principal Investigator: Tomas Ganz

Sponsor Name: NIH/National Institute Of Diabetes, Digestive and Kidney Disease

Award Title: "Bioiron 2011: From Basic Science to Medicine"

Principal Investigator: John A. Glaspy

Sponsor Name: Theradex

Award Title: "An Open-Label, Multiple-Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ONO-7746 In Adult Cancer Patients with Chemotherapy Induced Thrombocytopenia"

Principal Investigator: Sara Hurvitz

Sponsor Name: New Sponsor

Award Title: "PARP Inhibition After Preoperative Chemotherapy In Patients with Triple Negative Breast Cancer or ER/PR +, HER2 Negative with Known BRCA1/2 Mutations"

Principal Investigator: Steve Jacobsen

Sponsor Name: NIH/National Institute Of General Medical Sciences

Award Title: "Zhong: Actions of Drm3 on Drm2 Mediated DNA Methylation"

Principal Investigator: Marjorie Kagawa-Singer

Sponsor Name: NIH/National Cancer Institute

Award Title: "Culture, Social Support & Quality of Life: Asian American Breast Cancer Survivors"

Principal Investigator: Roger Lo

Sponsor Name: Melanoma Research Alliance 

Award Title: "Epigenetic Control of PDGFRBETA Expression In PLX4032 Acquired Resistance"

Principal Investigator: Gary J. Schiller

Sponsor Name: Pharmaceutical Research Associates, Inc.

Award Title: "An Open-Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 In Subjects with Relapsed or Refractory Leukemias"

Principal Investigator: Yi Tang

Sponsor Name: U.S. Army/Medical Research Acquisition Activity 

Award Title: "Intracellular Protein Delivery for Treating Breast Cancer"

Principal Investigator: John Timmerman

Sponsor Name:  Tower Cancer Research Foundation

Award Title: "Antibody-Interferon Fusion Proteins for Treatment of B-Cell Lymphomas"

Principal Investigator: Zev Wainberg

Sponsor Name: Eli Lilly and Company

Award Title: "Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product (IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Stomach"

Principal Investigator: Ernest Wright

Sponsor Name: Boehringer Ingelheim Pharmaceuticals, Inc.

Award Title: "Functional Characterization of Human SGLT5"


Last updated: 9/12/2011 10:18:51 AM